Multiple Sclerosis Drug Prices Rising By Double-Digits Despite Rebates
Report by the Massachusetts Attorney General’s office offers a unique view of net price trends because it is based on point-of-sale spending and hard-to-get rebate data.
You may also be interested in...
Center for Drug Evaluation and Research director accepts six-year term on Board of Governors of the Patient-Centered Outcomes Research Institute, which funds comparative effectiveness studies.
List pricing for Biogen’s Tecfidera and Novartis’ Gilenya would need to be discounted 47% and 50%, respectively, for them to be considered good values, ICER concludes in a new report. But three products come in under ICER's thresholds.
Program may provide drugs with narrower labels an opportunity to gain preferred formulary status versus entrenched market leaders.